Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of RX-10100 to Treat Major Depressive Disorder (MDD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females between 18 and 65 years old~* Diagnosis of MDD using DSM-IV criteria~* Have a score of 20 or more on the HAM-D-17~* Have a score of 4 or more on the CGI-S~* Written informed consent obtained~* Have a negative serum (P-HCG) pregnancy test at screening (for all women)~* Female subjects must meet one of the following criteria: (a) Be surgically sterile or (b) Agree that, if sexually active they will use oral contraceptives, double barrier contraception (E.g., condom with spermicide), intrauterine device, or other method approved by the sponsor.~Exclusion Criteria:~* Have a BMI \> 40 or \< 18~* Unstable angina pectoris~* History of myocardial infarction, stroke, or life-threatening arrhythmia within the prior 6 months~* Uncontrolled atrial fibrillation/flutter at screening~* Severe chronic or acute liver disease; history of moderate or severe hepatic impairment~* Clinically significant chronic hematological disease which may lead to priapism, such as sickle cell anemia and leukemia~* Bleeding disorder~* Resting hypotension or hypertension~* History of malignancy (cancers) within the past 5 years (other than squamous or basal cell skin cancer)~* NYHA Class III or IV heart failure~* Substance abuse/dependence within the past 6 months~* Significant suicidal ideation based on the C-SSRS~* Other current nondepressive Axis I disorders~* Depressive episode duration of less than 1 month or greater than 9 months~* Bipolar disorder~* Dysthmic disorder~* Borderline personality disorder~* Psychotic disorder/current psychotic features~* Any abnormal findings on the screening ECG judged clinically significant by the Investigator~* Any medical condition that is not stabilized or is anticipated to require hospitalization within 6 months, in the opinion of the Investigator~* Any history of cholestatic jaundice or liver cirrhosis~* Hyper- or hypothyroidism unless the subject has received a stable dose of thyroid medication for at least 3 months prior to the screening visit~* Women, who are breast-feeding, have been lactating within 3 months prior to screening~* Concurrent psychotherapy~* Subjects who have received any other investigational drug (including placebo) within 30 days before Visit 1~* Use of any treatment for MDD within 7 days of Visit 1 (14 days for fluoxetine) and during the study other than the study medication~* Use of antidepressants, anxiolytics, or other psychoactive drugs within 14 days of Visit 1 and during the study~* Concomitant use of antibiotics in the penicillin class (for the reduction of the potential for any additive or synergistic hepatotoxicity)~* A positive urine drug screen~* Elevation of AST and/or ALT \> 3 times the upper limit of normal (ULN)~* Diabetic subjects with an HbAlc ≥ 12%~* Any abnormal screening laboratory values judged clinically significant by the Investigator~* Previous nonresponse or hypersensitivity to two or more trials of antidepressant medication given in adequate doses and duration for the treatment of symptoms present in the current illness~* Subjects with known hypersensitivity to any antibiotic in the penicillin class~* Subjects who are illiterate or unable to understand the questionnaires~* Subjects who, in the opinion of the investigator, would be non-compliant with the visit schedule of study procedures~* Subjects who pose potential harm to others

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (w/o API)
- 2 (Type: EXPERIMENTAL): 5mg dose of RX-10100
- 3 (Type: EXPERIMENTAL): 10mg dose of RX-10100
- 4 (Type: EXPERIMENTAL): 15 mg dose of RX-10100

Based on this trial design, predict the completion outcome and termination type (if applicable).